AI-Designed Pan-TEAD Inhibitor Shows Promising Results for Mesothelioma
By: David Statman
October 30, 2026
Early results from a Phase 1 clinical trial of ISM6331, an investigational AI-designed cancer drug developed by Insilico Medicine, were presented at the European Society of...
Read Post








